Mid-Atlantic Division
CHTN2003CRCprog - Colorectal Carcinoma Progression
Code Key
| Code | Tissue type | # of cases* |
|---|---|---|
| Bnc | normal non-neoplastic colonic mucosa from non-cancer cases | 7 |
| Bc | normal non-neoplastic colonic mucosa from cancer cases | 7 |
| Bi | inflamed and or regenerative non-neoplastic mucosa (ulcerative colitis) | 6 |
| AS | adenomas, < 2cm in maximum dimension | 7 |
| AL | adenomas, > 2 cm in maximum dimension | 7 |
| CE | primary invasive adenocarcinoma, pathologic stage T1 or T2 | 7 |
| CL | primary invasive adenocarcinoma, pathologic stage T3 or T4 | 7 |
| LN | colorectal adenocarcinoma metastatic to lymph nodes, same cases as CL primary cancers | 7 |
| M | colorectal adenocarcinoma metastatic to distant sites | 7 |
| Con1 | Spleen (control tissue) | |
| Con2 | Kidney (control tissue) | |
|
*This number represents the number of cases selected in the original design of the TMA. Due to the non-uniformity inherent to tissue samples and histologic techniques, not all cases will be represented in all of the TMA sections. In quality assurance assessment of the TMA sections, a minimum of10 cases each of non-neoplastic mucosa, adenoma, primary carcinoma, and metastatic tumor must be present in at least one tissue spot. |
||
Cases
| TMA code | Diagnosis | Anatomic location of tissue sample | Gender | Age | pT stage* | N stage* | metastatic site | Other samples from same subject |
|---|---|---|---|---|---|---|---|---|
| Bnc1 | diverticulosis | D | M | 50 | NA | NA | NA | |
| Bnc2 | diverticulosis | D | M | 74 | NA | NA | NA | |
| Bnc3 | diverticulosis | P | M | 74 | NA | NA | NA | |
| Bnc4 | diverticulosis | P | M | 69 | NA | NA | NA | |
| Bnc5 | diverticulosis | D | F | 79 | NA | NA | NA | |
| Bnc6 | diverticulosis | D | M | 40 | NA | NA | NA | |
| Bnc7 | diverticulosis | D | F | 54 | NA | NA | NA | |
| Bi1 | ulcerative colitis | U | F | 11 | NA | NA | NA | |
| Bi2 | ulcerative colitis | P | M | 41 | NA | NA | NA | |
| Bi3 | ulcerative colitis | D | F | 15 | NA | NA | NA | |
| Bi4 | ulcerative colitis | D | M | 23 | NA | NA | NA | |
| Bi5 | ulcerative colitis | P | F | 40 | NA | NA | NA | |
| Bi6 | ulcerative colitis | D | M | 43 | NA | NA | NA | |
| Bc1 | mucosa adjacent to adenocarcinoma | P | M | 63 | T3 | N2 | NA | CL1, LN1 |
| Bc2 | mucosa adjacent to adenocarcinoma | D | M | 52 | T3 | N1 | NA | CL2, LN2 |
| Bc3 | mucosa adjacent to adenocarcinoma | D | M | 62 | T3 | N2 | NA | CL3, LN3 |
| Bc4 | mucosa adjacent to adenocarcinoma | P | M | 71 | T3 | N2 | NA | AS3, AL1,CL4, LN4 |
| Bc5 | mucosa adjacent to adenocarcinoma | U | F | 51 | T3 | N2 | NA | AS4, CL5, LN5 |
| Bc6 | mucosa adjacent to adenocarcinoma | P | F | 57 | T3 | N2 | NA | CL6, LN6 |
| Bc7 | mucosa adjacent to adenocarcinoma | P | F | 42 | T3 | N1 | NA | CL7, LN7 |
| AS1 | tubular adenoma | D | M | 48 | NA | NA | NA | AS5 |
| AS2 | tubular adenoma | P | F | 59 | NA | NA | NA | |
| AS3 | tubular adenoma | P | M | 71 | NA | NA | NA | BC4, AL1,CL4, LN4 |
| AS4 | tubular adenoma | D | F | 51 | NA | NA | NA | BC5, CL5, LN5 |
| AS5 | tubular adenoma | D | M | 48 | NA | NA | NA | AS1 |
| AS6 | tubular adenoma | D | M | 71 | NA | NA | NA | |
| AS7 | tubular adenoma | P | M | 58 | NA | NA | NA | |
| AL1 | tubulovillous adenoma | P | M | 71 | NA | NA | NA | BC4, AS3,CL4, LN4 |
| AL2 | villous adenoma | D | M | 67 | NA | NA | NA | |
| AL3 | villous adenoma | P | F | 48 | NA | NA | NA | CE5 |
| AL4 | tubulovillous adenoma | P | M | 58 | NA | NA | NA | CE7 |
| AL5 | tubulovillous adenoma | U | F | 45 | NA | NA | NA | |
| AL6 | tubulovillous adenoma | U | F | 70 | NA | NA | NA | |
| AL7 | tubulovillous adenoma | P | M | 63 | NA | NA | NA | |
| CE1 | adenocarcinoma | D | M | 67 | T2 | N1 | NA | |
| CE2 | adenocarcinoma | D | M | 83 | T2 | N0 | NA | |
| CE3 | adenocarcinoma | D | M | 67 | T2 | N1 | NA | |
| CE4 | adenocarcinoma | P | F | 58 | T1 | N0 | NA | |
| CE5 | adenocarcinoma | D | F | 48 | T1 | N0 | NA | AL3 |
| CE6 | adenocarcinoma | P | M | 57 | T2 | N0 | NA | |
| CE7 | adenocarcinoma | D | M | 58 | T2 | N0 | NA | AL4 |
| CL1 | adenocarcinoma | P | M | 63 | T3 | N2 | NA | Bc1, LN1 |
| CL2 | adenocarcinoma | D | M | 52 | T3 | N1 | NA | Bc2, LN2 |
| CL3 | adenocarcinoma | D | M | 62 | T3 | N2 | NA | Bc3, LN3 |
| CL4 | adenocarcinoma | P | M | 71 | T3 | N2 | NA | Bc4, AS3, AL1, LN4 |
| CL5 | adenocarcinoma | D | F | 51 | T3 | N2 | NA | Bc5, AS4, LN5 |
| CL6 | adenocarcinoma | P | F | 57 | T3 | N2 | NA | Bc6, LN6 |
| CL7 | adenocarcinoma | P | F | 42 | T3 | N1 | NA | Bc7, LN7 |
| LN1 | adenocarcinoma | NA | M | 63 | T3 | N2 | lymph node | Bc1, CL1 |
| LN2 | adenocarcinoma | NA | M | 52 | T3 | N1 | lymph node | Bc2, CL2 |
| LN3 | adenocarcinoma | NA | M | 62 | T3 | N2 | lymph node | Bc3, CL3 |
| LN4 | adenocarcinoma | NA | M | 71 | T3 | N2 | lymph node | Bc4, AS3, AL1,CL4, |
| LN5 | adenocarcinoma | NA | F | 51 | T3 | N2 | lymph node | Bc5, AS4, CL5 |
| LN6 | adenocarcinoma | NA | F | 57 | T3 | N2 | lymph node | Bc6, CL6 |
| LN7 | adenocarcinoma | NA | F | 42 | T3 | N1 | lymph node | Bc7, CL7 |
| M1 | adenocarcinoma | NA | M | 68 | NA | NA | liver | |
| M2 | adenocarcinoma | NA | M | 51 | NA | NA | liver | |
| M3 | adenocarcinoma | NA | M | 71 | NA | NA | liver | |
| M4 | adenocarcinoma | NA | F | 52 | NA | NA | liver | |
| M5 | adenocarcinoma | NA | M | 66 | NA | NA | lung | |
| M6 | adenocarcinoma | NA | M | 71 | NA | NA | lung | |
| M7 | adenocarcinoma | NA | M | 57 | NA | NA | lung | |
| *American Joint Committee on Cancer | ||||||||
| Cancer Staging Manual, 5th Ed. | ||||||||
| †P = proximal (cecum, ascending, transverse colon), D = distal (descending, sigmoid colon & rectum), U = unknown, NA = not applicable | ||||||||